Vaccines
3 October 2017
PnuVax Awarded $29.4 Million USD Grant to Advance Innovative Vaccine into Clinical Trials28 September 2017
Moderna Announces Publication in Molecular Therapy Characterizing Potent Immune Response Generated by Its mRNA Prophylactic Vaccines27 September 2017
Aduro Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Personalized Immunotherapy pLADD Based on Proprietary Neoantigen Technology25 September 2017
Sinovac Reports Preliminary Top-Line Results from Phase III Clinical Trial for Varicella Vaccine Candidate Against Chickenpox21 September 2017
Bavarian Nordic Provides Update on its Universal RSV Vaccine19 September 2017
Transgene: First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers18 September 2017
Inovio and Partners Initiate Phase 1/2a Clinical Trial To Further Advance Its Vaccine Against Deadly MERS Infection15 September 2017
Independent Data Monitoring Committee Recommends Discontinuation of Bavarian Nordic’s Phase 3 Study of PROSTVAC in Metastatic Prostate Cancer14 September 2017
Successful Phase III trial for ALK’s tree allergy SLIT-tablet14 September 2017
OncBioMune Meets Primary Objective in Trial of ProscaVax Immunotherapy Vaccine for Prostate Cancer14 September 2017
Argos Therapeutics Reports on Interim Analysis of Phase 3 ADAPT Trial Presented at ESMO 2017 Congress14 September 2017
FDA Advisory Committee votes unanimously for Shingrix (HZ/su) in the US for prevention of herpes zoster (shingles) in adults ages 50 and over11 September 2017
Inovio’s Cancer Immunotherapy (INO-5150) Slowed PSA Rise and Significantly Increased PSA Doubling Times In Patients with Recurrent Prostate Cancer8 September 2017
New Randomized Data From CMB305 + Checkpoint Inhibitor Study Demonstrate Greater Clinical Benefit and Immune Response7 September 2017
Anergis Announces Top Line Results from Large-Scale ATIBAR Trial with Ultra-Fast Allergy Immunotherapy AllerT6 September 2017
Argos Announces First Dosing of HIV Patient with AGS-004 Derived from the Latent Viral Reservoir6 September 2017
Aelix Therapeutics Enrolls First Patient In Company’s Initial Therapeutic HIV Vaccine Clinical Trial5 September 2017
VAXIMM Announces Preclinical Results with Novel Oral T-cell Cancer Immunotherapies Being Presented at Third CRI-CIMT-EATI-AACR Conference1 September 2017
PepVax begins efficacy study for lead candidate29 August 2017
Gliknik Announces Dosing Of First Patient In Phase 2 Trial Targeting Prevention Of Recurrence Of High-Risk Oral Cavity Cancer21 August 2017
Altimmune Submits Investigational New Drug Application for NasoVAX in Preparation for Phase 2 Trial16 August 2017
VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for VBI-1901 to Treat Glioblastoma MultiformeNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe